SpeeDx to break ground for new facility

2019 06 11 20 36 8064 Neisseria Gonorrhoeae Gonorrhea 400

SpeeDx announced it will expand its U.S.-based operations with the construction of new clinical testing facilities in Austin, TX.

The site will house a range of instrumentation to facilitate clinical trial testing activities in addition to its diagnostic services, the company said.

SpeeDx is an Australian-based private company with subsidiary offices in Austin and London and distributors across Europe. The company specializes in molecular diagnostic tests based on real-time polymerase chain reaction (qPCR) technology.

In June, SpeeDx received breakthrough device designation from the U.S. Food and Drug Administration for its ResistancePlus GC test for detecting Neisseria gonorrhoeae bacteria.

Page 1 of 15
Next Page